AU756762B2 - Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases - Google Patents

Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases Download PDF

Info

Publication number
AU756762B2
AU756762B2 AU19072/99A AU1907299A AU756762B2 AU 756762 B2 AU756762 B2 AU 756762B2 AU 19072/99 A AU19072/99 A AU 19072/99A AU 1907299 A AU1907299 A AU 1907299A AU 756762 B2 AU756762 B2 AU 756762B2
Authority
AU
Australia
Prior art keywords
alkyl
group
compound
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19072/99A
Other languages
English (en)
Other versions
AU1907299A (en
Inventor
Walter R. Bishop
Joseph J. Catino
David L. Cutler
Ronald J. Doll
Ashit Ganguly
Viyyoor Girijavallabhan
Paul Kirschmeier
Ming Liu
Loretta L. Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU756762(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU1907299A publication Critical patent/AU1907299A/en
Application granted granted Critical
Publication of AU756762B2 publication Critical patent/AU756762B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU19072/99A 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases Ceased AU756762B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US08/996027 1997-12-22
US14352998A 1998-08-28 1998-08-28
US09/143529 1998-08-28
US18196998A 1998-10-29 1998-10-29
US09/181969 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (2)

Publication Number Publication Date
AU1907299A AU1907299A (en) 1999-07-12
AU756762B2 true AU756762B2 (en) 2003-01-23

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19072/99A Ceased AU756762B2 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (enExample)
JP (1) JP4502503B2 (enExample)
KR (1) KR100700907B1 (enExample)
CN (1) CN1129431C (enExample)
AR (1) AR017440A1 (enExample)
AT (1) ATE317697T1 (enExample)
AU (1) AU756762B2 (enExample)
BR (1) BR9814419A (enExample)
CA (1) CA2315693C (enExample)
CL (1) CL2007001889A1 (enExample)
CO (1) CO5080764A1 (enExample)
CZ (1) CZ298511B6 (enExample)
DE (1) DE69833509T2 (enExample)
DK (1) DK1041985T3 (enExample)
ES (1) ES2255196T3 (enExample)
HU (1) HUP0102473A3 (enExample)
IL (1) IL136462A0 (enExample)
MY (1) MY137303A (enExample)
NO (1) NO326832B1 (enExample)
NZ (1) NZ504928A (enExample)
PE (1) PE20000042A1 (enExample)
PT (1) PT1041985E (enExample)
SK (1) SK285584B6 (enExample)
TW (1) TW581763B (enExample)
WO (1) WO1999032114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
ES2234692T3 (es) * 1999-11-09 2005-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimetricas en asociacion con otro agente anti-canceroso para una utilizacion terapeutica en el tratamiento del cancer.
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU2001235496A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064198A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US20030185831A1 (en) * 2001-11-30 2003-10-02 Schering Corporation Methods of treating cancer using an FPT inhibitor and antineoplastic
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
WO1992011034A1 (en) * 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
WO1997005902A1 (fr) * 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale
CA2240846C (en) * 1995-12-22 2002-07-16 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997033552A1 (en) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
EP0959883A4 (en) * 1996-04-03 2001-05-09 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
CA2251716A1 (en) * 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
EP0952842A2 (en) * 1996-04-18 1999-11-03 Merck & Co., Inc. A method of treating cancer
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
CN1248731C (zh) * 1997-02-18 2006-04-05 坎吉公司 肿瘤抑制基因与化学药物在制备用于治疗肿瘤的药物组合物中的联合应用

Also Published As

Publication number Publication date
AU1907299A (en) 1999-07-12
CN1129431C (zh) 2003-12-03
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
CN1284875A (zh) 2001-02-21
SK285584B6 (sk) 2007-04-05
JP4502503B2 (ja) 2010-07-14
NZ504928A (en) 2004-12-24
NO326832B1 (no) 2009-02-23
EP1041985B1 (en) 2006-02-15
PT1041985E (pt) 2006-07-31
HUP0102473A3 (en) 2003-07-28
KR20010033452A (ko) 2001-04-25
MY137303A (en) 2009-01-30
JP2001526224A (ja) 2001-12-18
CO5080764A1 (es) 2001-09-25
CZ298511B6 (cs) 2007-10-24
NO20003229D0 (no) 2000-06-21
CZ20002236A3 (cs) 2001-04-11
CL2007001889A1 (es) 2008-01-11
DK1041985T3 (da) 2006-06-19
PE20000042A1 (es) 2000-02-17
SK8982000A3 (en) 2001-04-09
IL136462A0 (en) 2001-06-14
NO20003229L (no) 2000-08-22
TW581763B (en) 2004-04-01
AR017440A1 (es) 2001-09-05
DE69833509D1 (de) 2006-04-20
WO1999032114A1 (en) 1999-07-01
EP1041985A1 (en) 2000-10-11
DE69833509T2 (de) 2006-10-26
CA2315693C (en) 2010-11-30
KR100700907B1 (ko) 2007-03-29
ATE317697T1 (de) 2006-03-15
HUP0102473A2 (hu) 2002-01-28
ES2255196T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
US6333333B1 (en) Methods for treating proliferative diseases
AU756762B2 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
ES2275505T3 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores.
RU2264217C2 (ru) Синергические способы и композиции для лечения рака
US6703400B2 (en) Methods for treating multidrug resistance
CN106456795A (zh) 靶向治疗学
AU2002211862B2 (en) Methods of inducing cancer cell death and tumor regression
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
JP2005504065A (ja) 癌治療のための組成物および方法
US20120202789A1 (en) Compositions and methods for the treatment of cancer
MXPA00006257A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
US20040176403A1 (en) Methods for treating multidrug resistance
EP3777852A1 (en) Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
AU2005248948A1 (en) Methods of inducing cancer cell death and tumor regression

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)